Kyverna Therapeutics

The page describes Kyverna's work to address the need for new therapeutic approaches that could result in sustained treatment-free remission from autoimmune disease.

Patients that qualify for a clinical trial or expanded access will be provided with a step-by-step explanation of the procedures involved and the associated risks.

Discover CAR T-cell therapy for multiple sclerosis. CAR T-cell therapy involves modifying a patient’s T cells to recognize and remove B cells in the patient’s body.

Working to demonstrate the clinical potential of Kyverna’s autoimmune therapies to ideally achieve a sustained, treatment-free remission.

The page offers educational resources and upcoming events related to the company's work to develop treatments for autoimmune diseases.

The page features publications and contributions on CAR T-cell therapies.

The page shows before-and-after videos of a patient treated in KYSA-8, a registrational Phase 2 trial of miv-cel (mivocabtagene autoleucel, KYV-101) in stiff person syndrome, at 16 weeks and one year.

— Kyverna to lead and fund preclinical and clinical development; Intellia to receive option to co-develop and co-promote with lead U.S. commercialization rights —

Kyverna Therapeutics announced exclusive worldwide licenses from the National Institutes of Health for intellectual property related to a clinical-stage anti-CD19 CAR T construct for autoimmune diseases.

Dr. Chung brings nearly 20 years’ experience as a leader in autoimmune disease drug development with expertise in rheumatology, autoimmunity, and immunology

Former Genentech CEO Ian Clark will guide Kyverna’s vision to transform the treatment of autoimmune diseases through engineered cell therapies

Kyverna offers employees compensation and benefits intended to support their health and well-being.

Professor Georg Schett researches rheumatic and autoimmune disease pathogenesis. In 2008, Professor Georg Schett and colleagues launched the German Research Foundation-funded IMMUNOBONE program to study skeletal and immune system interactions.

The page introduces the Kyverna team and its work on patient-centricity, industry experience, and academic enthusiasm.

Mr. Aktar has over two decades of biopharmaceutical experience, including more than a decade of technical leadership in cell and gene therapy, as well as experience in corporate strategy and business development. He is Chief Executive Officer of Receptive Bio, a privately held biotechnology company.

Naji Gehchan is Chief Medical and Development Officer at Kyverna Therapeutics and oversees research, clinical development, regulatory, and medical affairs. Naji Gehchan previously worked at Eli Lilly and Company.

Discover Kyverna, a patient-centered, clinical-stage biopharmaceutical company with active, ongoing clinical trials for multiple autoimmune diseases at different locations across the world.

The page outlines Kyverna's credo and core values for autoimmune therapy.

Kyverna works on cell therapy for autoimmune diseases.

Discover Kyverna, a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases.

EU GDPR and the UK Data Protection Act 2018 require the data controller to provide information about data processing to data subjects in the EEA and UK.

Kyverna Therapeutics, Inc. and its subsidiaries and affiliates describe their privacy practices for the www.kyvernatx.com website and the rights and choices available to individuals regarding their information.